Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis.

Please provide your email address to receive an email when new articles are posted on . Results of a randomized control trial of patients with advanced cirrhosis without recent fluoroquinolone therapy ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...

FRANKLIN LAKES, N.J., June 23, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from ...

Research, headed by teams at Trinity College Dublin and University College Dublin, has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body’s ...

SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver ...

Clinical-stage biotech BioVie (NASDAQ:BIVI) announced Monday that the company halted patient enrollment in Phase 2b clinical trial for ascites candidate BIV201 after generating "compelling" data from ...

MAY 9, 2025, NEW YORK – A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies. Led by Ludwig ...

Background: Ascites and pleural effusion are well recognized complications of pancreatic diseases. Drug therapy of these is limited by high cost, prolonged hospitalization and failure rates; surgery ...

Cancer is the rapid, uncontrollable proliferation of mutated cells that spread within tissue and eventually throughout the body. Cancer types are dependent on the specific tissue in which tumors arise ...

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...